APA (7th ed.) Citation

Adler, S., Reichenbach, S., Gloor, A., Yerly, D., Cullmann, J. L., & Villiger, P. M. (2019). Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology, 58(9), 1639. https://doi.org/10.1093/rheumatology/kez091

Chicago Style (17th ed.) Citation

Adler, Sabine, Stephan Reichenbach, Andrea Gloor, Daniel Yerly, Jennifer L. Cullmann, and Peter M. Villiger. "Risk of Relapse After Discontinuation of Tocilizumab Therapy in Giant Cell Arteritis." Rheumatology 58, no. 9 (2019): 1639. https://doi.org/10.1093/rheumatology/kez091.

MLA (9th ed.) Citation

Adler, Sabine, et al. "Risk of Relapse After Discontinuation of Tocilizumab Therapy in Giant Cell Arteritis." Rheumatology, vol. 58, no. 9, 2019, p. 1639, https://doi.org/10.1093/rheumatology/kez091.